中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

143 records (took 0.027 seconds)

    ANTI-CD38 HUMAN ANTIBODIES AND USES THEREOF
    103.
    发明申请
    ANTI-CD38 HUMAN ANTIBODIES AND USES THEREOF 审中-公开

    公开(公告)号：US20160096901A1

    公开(公告)日：2016-04-07

    申请号：US14958959

    申请日：2015-12-04

    Applicant: MorphoSys AG

    Inventor： Michael Tesar ,  Ute Jaeger

    IPC: C07K16/40

    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.

    TREATMENT FOR RHEUMATOID ARTHRITIS
    105.
    发明申请
    TREATMENT FOR RHEUMATOID ARTHRITIS 审中-公开
    治疗风湿性关节炎

    公开(公告)号：US20150246969A1

    公开(公告)日：2015-09-03

    申请号：US14429996

    申请日：2013-09-19

    Applicant: MORPHOSYS AG

    Inventor： Stefan Hartle ,  Stephane Leclair ,  Amgad Shebl ,  Stefan Steidl

    IPC: C07K16/24 ,  A61K31/519 ,  A61K39/395

    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

    Abstract translation: 本发明提供用于治疗类风湿性关节炎的抗GM-CSF抗体。 将抗GM-CSF抗体，特别是MOR103，以有利于临床环境的剂量施用于患有类风湿性关节炎的患者。

    ANTI-CD38 HUMAN ANTIBODIES AND USES THEREFOR
    106.
    发明申请
    ANTI-CD38 HUMAN ANTIBODIES AND USES THEREFOR 审中-公开
    抗CD38人类抗体及其用途

    公开(公告)号：US20150232571A1

    公开(公告)日：2015-08-20

    申请号：US14630042

    申请日：2015-02-24

    Applicant: MORPHOSYS AG

    Inventor： Michael Tesar ,  Ute Jager

    IPC: C07K16/30

    CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K16/005 ,  C07K16/3061 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2319/30 ,  C12N9/2497 ,  C12Y302/02024

    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.

    Abstract translation: 本发明提供重组抗原结合区和抗体以及含有CD38特异性抗原结合区的功能片段，其在各种病症或病症中起积分作用。 因此，这些抗体可用于治疗例如血液恶性肿瘤例如多发性骨髓瘤。 本发明的抗体也可用于诊断领域，以及用于研究CD38在恶性肿瘤相关疾病进展中的作用。 本发明还提供了编码前述抗体的核酸序列，含有该抗体的载体，药物组合物和具有使用说明书的试剂盒。 本发明还提供CD38的分离的新型表位和因此使用的方法。

    Generation of specific binding partners binding to (poly)peptides encoded by genomic DNA fragments or ESTs
    108.
    发明申请
    Generation of specific binding partners binding to (poly)peptides encoded by genomic DNA fragments or ESTs 审中-公开
    生成与基因组DNA片段或EST编码的（多）肽结合的特异性结合配偶体

    公开(公告)号：US20040157291A1

    公开(公告)日：2004-08-12

    申请号：US10662824

    申请日：2003-09-16

    Applicant: Morphosys AG

    Inventor： Christian Frisch ,  Titus Kretzschmar ,  Adolf Hoss ,  Thomas Von Ruden

    IPC: C07H021/04 ,  C07K016/10

    CPC classification number: C40B40/02 ,  C07K16/1018 ,  C07K16/2845 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2319/00 ,  C12N15/1037

    Abstract: The present invention relates to the generation of specific binding partners binding to (poly)peptides encoded by genomic DNA fragments or ESTs. The (poly)peptides are expressed as part of fusion proteins which are forming inclusion bodies on expression in host cells. The inclusion bodies are used to generate binding partners which bind specifically to said (poly)peptides. The specific binding partners, in particular immunoglobulins or fragments thereof, are useful for analysis and functional characterisation of proteins encoded by nucleic acid sequences comprising the corresponding genomic DNA fragments or ESTs. The invention further relates to nucleic acid molecules, vectors and host cells to be used in the methods of the present invention. The invention further relates to the use of fusion proteins comprising the first N-terminal domain of the geneIII protein of filamentous phage as fusion partner for the expression of a (poly)peptide/protein fused to said fusion partner, and to methods for the expression of (poly)peptide/proteins.

    Abstract translation: 本发明涉及与由基因组DNA片段或EST编码的（多）肽结合的特异性结合配偶体的产生。 （多）肽被表达为在宿主细胞中在表达上形成包涵体的融合蛋白的一部分。 包涵体用于产生特异性结合所述（多）肽的结合配偶体。 特异性结合配偶体，特别是免疫球蛋白或其片段，可用于由包含相应基因组DNA片段或EST的核酸序列编码的蛋白质的分析和功能表征。 本发明还涉及用于本发明方法的核酸分子，载体和宿主细胞。 本发明还涉及包含丝状噬菌体的基因III蛋白的第一N末端结构域的融合蛋白在与所述融合伴侣融合的（多）肽/蛋白质的表达的融合伴侣中的用途，以及表达方法 的（多）肽/蛋白质。

Patent Agency Ranking